Related Experiment Video
Updated: May 29, 2026
06:25
Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
Pharmacokinetic evaluation of pramipexole
Angelo Antonini1, Daniela Calandrella
1Department for Parkinson Disease, IRCCS San Camillo, Venice, Italy. angelo3000@yahoo.com
Expert Opinion on Drug Metabolism & Toxicology
|September 7, 2011
Summary
Pramipexole dihydrochloride, used for Parkinson's disease and restless legs syndrome, now has an extended-release formulation. This new formulation offers improved convenience and potentially more stable drug delivery for patients.
Area of Science:
- Pharmacology
- Neurology
- Drug Development
Background:
- Immediate-release (IR) pramipexole dihydrochloride treats Parkinson's disease (PD) and restless legs syndrome (RLS).
- An extended-release (ER) formulation has been developed for once-daily administration.
- The ER formulation aims for more stable dopaminergic stimulation in PD patients.
Purpose of the Study:
- To review the pharmacokinetic profile of both IR and ER pramipexole formulations.
- To discuss determinants of pramipexole peripheral pharmacokinetics.
- To explore the role of genetic and clinical factors in drug efficacy.
Main Methods:
- Review of existing pharmacokinetic data for IR and ER pramipexole.
- Analysis of factors influencing pramipexole's peripheral pharmacokinetics.
- Examination of genetic and clinical determinants of efficacy.
Main Results:
- Pramipexole is a D3-selective dopamine agonist with low affinity for other receptors.
- It lacks the risks of valvular heart disease and fibrosis associated with ergot-derived agonists.
- The ER formulation provides stable plasma levels, enhancing convenience and adherence.
Conclusions:
- The once-daily ER pramipexole formulation offers significant patient advantages.
- Benefits include convenience, improved treatment adherence, and potentially reduced dyskinesia risk.
- ER pramipexole may facilitate more continuous drug delivery, particularly beneficial in early PD treatment.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...